Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Research ArticleOriginal Article

FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma

Tao Chen, Fei Wang, Shupei Wei, Yingjie Nie, Xiaotao Zheng, Yu Deng, Xubin Zhu, Yuezhen Deng, Nanshan Zhong and Chengzhi Zhou
Cancer Biology & Medicine August 2021, 18 (3) 665-674; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0389
Tao Chen
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fei Wang
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shupei Wei
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yingjie Nie
2NHC Key Laboratory of Pulmonary Immunological Diseases, Clinical Research Lab Center, Guizhou Provincial People’s Hospital, Guiyang OK 550002, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaotao Zheng
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Deng
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xubin Zhu
3Longgang Central Hospital of Shenzhen, Affiliated Shenzhen Longgang Central Hospital of Zunyi Medical College, Shenzhen 518116, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuezhen Deng
4Center for Molecular Medicine, Xiangya Hospital, Central South University, Changsha 410078, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nanshan Zhong
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chengzhi Zhou
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chengzhi Zhou
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    PD166866 induces senescence of lung squamous cell carcinoma cells. (A) NCI-H226 and H1703 cells were treated with PD166866, and the tyrosine phosphorylation of FGFR was detected with immunoprecipitation and Western blot analyses. (B) NCI-H226 and H1703 cells were treated with PD166866, and anchorage-independent growth was detected with soft agar colony assays. (C, D) NCI-H226 and H1703 cells were treated with PD166866, and β-gal staining was used to detect cell senescence. Statistical analyses were performed. (E) FGFR 1 was knocked down in NCI-H226 cells, and β-gal staining was used to detect cell senescence. Statistical analyses were performed. **P < 0.01.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Knockdown of RACK1 induces senescence of lung squamous cell carcinoma cells. (A) RACK1 expression in NCI-H226 and H1703 cells was detected. (B) RACK1 was knocked down in NCI-H226 and H1703 cells, and anchorage-independent growth was detected with colony formation assays. (C) β-gal staining was used to detect cell senescence. (D) RACK1 expression was knocked down in NCI-H226 and H1703 cells, subcutaneous tumorigenesis assays were performed, and the tumor weights were statistically analyzed. (E) Immunohistochemistry was used to detect the expression of Ki67 in tumors derived from RACK1 knockdown NCI-H226 cells (20x). Left: representative immunohistochemistry image; right: RACK1 and MDM2 protein levels in tumors. **P < 0.01.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Interaction between RACK1 and MDM2. (A) The interaction between the GST-RACK1 fusion protein and MDM2 was detected with GST pull-down assays. Ten micrograms of the fusion protein GST-RACK1 was incubated with NCI-H226 cell lysate. (B) The interaction between myc-RACK1 and Flag-MDM2 expressed in NCI-H226 cells was detected by immunoprecipitation. Four micrograms of myc-RACK1 and Flag-MDM2 plasmids was transfected into the cells, and the proteins were collected for immunoprecipitation 48 h later. (C) The interaction between RACK1 and MDM2 expressed in NCI-H226 cells was detected by immunoprecipitation. (D) The interactions among FGFR, RACK1, and MDM2 expressed in NCI-H226 cells were detected by immunoprecipitation. (E) The interaction between the exogeneous proteins myc-RACK1 and Flag-MDM2 expressed in NCI-H226 cells was detected by immunoprecipitation. Four micrograms of myc-RACK1 and Flag-MDM2, HA-p53, and Flag MDM2 plasmids was transfected into the cells, which were collected 48 h after transfection.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    RACK1 promotes the ubiquitination of p53. (A) Overexpression of RACK1 in NCI-H226 cells promoted the ubiquitination of p53. (B) Overexpression of RACK1 in NCI-H226 and H1703 cells inhibited the p53 and p21 protein levels. (C) Treatment of NCI-H226 and H1703 cells with PD166866 increased the protein levels of p53 and p21. (D) The effects of PD166866 on the interaction between RACK1 and MDM2 were detected by immunoprecipitation.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    PD166866 and RG7112 cooperatively inhibit the malignancy of lung cancer. (A) PD166866 combined with RG7112 inhibited the colony formation of NCI-H226 and H1703 cells. (B) PD166866 combined with RG7112 promoted the expression of p53 and p21. (C) PD166866 combined with RG7112 inhibited the distal seeding of NCI-H226 cells. The gross morphology of lungs is shown. H&E staining was performed, and the numbers of foci were analyzed (10x). **P < 0.01; ##P < 0.01.

  • Figure 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6

    Schematic of the proposed mechanism(s) for FGFR/RACK1 interaction with MDM2 to inhibit the senescence of lung squamous cell carcinoma. The interaction of FGFR/RACK1 with MDM2 promotes the degradation of P53 (left); the FGFR inhibitor PD166866 and the MDM2/p53 inhibitor RG7112 cooperatively decrease the interactions between RACK1 and MDM2; weaken the interaction between MDM2/p53; and induce the accumulation of p53 and the upregulation of p21 and consequently cell senescence.

PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 18 (3)
Cancer Biology & Medicine
Vol. 18, Issue 3
1 Aug 2021
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma
Tao Chen, Fei Wang, Shupei Wei, Yingjie Nie, Xiaotao Zheng, Yu Deng, Xubin Zhu, Yuezhen Deng, Nanshan Zhong, Chengzhi Zhou
Cancer Biology & Medicine Aug 2021, 18 (3) 665-674; DOI: 10.20892/j.issn.2095-3941.2020.0389

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma
Tao Chen, Fei Wang, Shupei Wei, Yingjie Nie, Xiaotao Zheng, Yu Deng, Xubin Zhu, Yuezhen Deng, Nanshan Zhong, Chengzhi Zhou
Cancer Biology & Medicine Aug 2021, 18 (3) 665-674; DOI: 10.20892/j.issn.2095-3941.2020.0389
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Conclusions
    • Grant support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer
  • Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma
  • Comparing effectiveness and safety of paclitaxel plus raltitrexed vs. paclitaxel alone in second-line palliative chemotherapy for metastatic gastric adenocarcinoma: A randomized phase II clinical trial
Show more Original Article

Similar Articles

Keywords

  • FGFR
  • RACK1
  • MDM2
  • P53
  • senescence

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2023 Cancer Biology & Medicine

Powered by HighWire